News

The Principal Investigator is Dr. James D. Blanchard, Principal Scientist, Preclinical Development at Aradigm. Professor Luiz Bermudez at Oregon State University, Corvallis, will lead the laboratory research as

Multikine (Leukocyte Interleukin Injection) is being investigated as a potential first-line immunotherapy. Its objective is to harness the immune system of the patient to produce an anti-tumor response.

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor, which is designed to uniquely tackle the body’s own immune system to help restore anti-tumor immune response. The combination,

The trial dubbed as OPH1004 had investigated the superiority of Fovista in combination with Eylea (aflibercept) or Avastin (bevacizumab) anti-VEGF therapy over Eylea or Avastin monotherapy. It was

Other partners include the Cell and Gene Therapy Catapult, Stratophase and Synthace, and the collaboration is co-funded by Innovate UK. The aim of the collaboration is to explore

Manufactured by the Florida-based PharmaTech, the liquid drug or dietary supplement products were distributed by Leader Brand, Major Pharmaceuticals and Rugby Laboratories. The distributors have all issued voluntary

The company has laid off 60 employees under the planned strategic actions, as well as pursuing strategic options for its research and development (R&D) assets. The reduction in

New investors include Sofinnova, Vivo Capital, F-Prime Capital Partners, certain investment funds advised by Clough Capital Partners L.P., and venBio Select. Existing investors Morningside Ventures, Cormorant Asset Management,

Gilead filed the NDA for BIC/FTC/TAF with a Priority Review voucher on June 12, 2017, and FDA has set a target action date under the Prescription Drug User